Earnings Summary

Ascendis Pharma A/S’s revenue fell -44.78% since last year same period to $1.17Mn in the Q3 2016. On a quarterly growth basis, Ascendis Pharma A/S has generated 2.9% jump in its revenue since last 3-months.

Ascendis Pharma A/S’s net profit fell -149.71% since last year same period to $-18.25Mn in the Q3 2016. On a quarterly growth basis, Ascendis Pharma A/S has generated -37.4% fall in its net profits since last 3-months.

Ascendis Pharma A/S’s net profit margin fell -352.22% since last year same period to -1561.51% in the Q3 2016. On a quarterly growth basis, Ascendis Pharma A/S has generated -33.52% fall in its net profit margins since last 3-months.

Ascendis Pharma A/S’s earning per share (EPS) estimates for the current quarter stand at -2.6 - a 3.35% jump from last quarter’s estimates.

Ascendis Pharma A/S’s earning per share (EPS) estimates for the current year stand at -2.6.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ascendis Pharma A/S’s return on assets (ROA) stands at -0.32.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ascendis Pharma A/S’s return on equity (ROE) stands at -1.02.